合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*

doi:10.3969/j.issn.1672-5069.2017.06.020

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (6): 720-723.doi: 10.3969/j.issn.1672-5069.2017.06.020

合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*

陈杰, 范作鹏, 梁珊, 聂巍, 仇丽霞, 杨海霞, 林伟, 刘义荣, 张晶, 胡中杰

100069 北京市首都医科大学附属北京佑安医院丙型肝炎与中毒性肝病科

收稿日期:2016-12-30 出版日期:2017-11-10 发布日期:2017-12-14
通讯作者: 胡中杰, E-mail:yfcyt@139.com
基金资助:
北京市科技计划项目（编号:Z121107001012086）; 中国肝炎防治基金会天晴肝病研究基金项目（编号：TQGB20140052）

Features of chronic cholestatic liver disease,as a kind of drug-induced liver injury

Chen Jie, Fan Zuopeng, Liang Shan

Department of Hepatitis C & Toxic Liver Diseases,You’an Hospital,Capital Medical University,Beijing 100069,China

Received:2016-12-30 Online:2017-11-10 Published:2017-12-14

摘要/Abstract

摘要： 目的探讨慢性药物性胆汁淤积性肝病的病因、临床特点及对治疗应答的影响。方法2011年1月~2013年12月在我院住院治疗的慢性药物性肝损伤（DILl）患者87例,其中23例呈胆汁淤积性肝病（CLD）表现,不伴有胆汁淤积症的慢性DILI患者64例,比较两组临床资料的异同。结果在23例CLD患者中,肝细胞型11例、胆汁淤积型7例、混合型5例,在64例DILI患者中,肝细胞型50例,胆汁淤积型4例,混合型10例,两组临床分型差异具有统计学意义（P<0.01）;引起两组发病的药物占比无统计学差异（P>0.05）;23例CLD患者血清GGT和ALP分别为【430.7（156.00,1142.00)】U/L和（285.07±131.52） U/L,显著高于64例DILI患者的【111.5（18.00,185.60）】U/L和（140.28±101.36） U/L（P<0.05）;两组血清ALT、GGT、ALP和TBIL复常时间差异无统计学意义（P>0.05）。结论慢性药物性胆汁淤积性肝病患者兼具肝脏炎症和胆汁淤积的临床表现,经积极治疗后近期预后好。

关键词: 药物性肝损伤, 胆汁淤积性肝病, 临床特点, 预后

Abstract: Objective To summarize the features of chronic cholestatic liver disease（CLD）,as a kind of drug-induced liver injury（DILI）. Methods 87 patients with DILI were recruited between Jan. 2011 and Dec. 2013 in this study. The diagnosis was made by RUCAM score of equal to or greater than six at the base of exclusion. Results The clinical classification presented as CLD in 23,and as DILI without intrahepatic cholestasis in 64 cases,and the cholestatic disease was found more common in CLD patients（P<0.01）;the triggering medicines,including Chinese herbal medicines in the two groups,was not significantly different （P>0.05）;serum gamma-glutamyl transpeptidase （GGT） and alkaline phosphates （ALP） levels in 23 patients with CLD were 【430.7（156.00,1142.00）】 U/L and（285.07±131.52） U/L,much higher than【111.5（18.00,185.60）】 U/L and （140.28±101.36） U/L（P<0.05） in 64 patients with DILI;the recovering time for serum alanine aminotransferase,GGT,ALP and bilirubin back to normal in the two groups was not significantly different（P>0.05）. Conclusions The patients with chronic drug induced cholestatic liver disease have clinical manifestations of liver inflammation and cholestasis. They might get good prognosis in the short-term observation.

Key words: Drug-induced liver diseases, Cholestatic liver disease, Clinical characteristics, Prognosis

陈杰, 范作鹏, 梁珊, 聂巍, 仇丽霞, 杨海霞, 林伟, 刘义荣, 张晶, 胡中杰. 合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*[J]. 实用肝脏病杂志, 2017, 20(6): 720-723.

Chen Jie, Fan Zuopeng, Liang Shan. Features of chronic cholestatic liver disease,as a kind of drug-induced liver injury[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 720-723.

参考文献

[1] 曹旬旬,高月求,张文宏,等. 基于上海市住院慢性肝病患者胆汁淤积患病率的调查研究. 中华肝脏病杂志,2015,23（8）:569-573.
[2] Chalasani NP,Hayashi PH,Bonkovsky HL,et al. ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-
induced liver injury. Am J Gastroenterol,2014,109（7）:950-966.
[4] Danan G,Beniehou C．Causality assessment of adverse reactions to drugs-A novel method based on the conclusions of international consensus meetings：application to drug-induced liver injuries．J Clin Epidemiol,1993,46：1323-1330．
[5] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 中华肝脏病杂志,2015,23（11）:810-820.
[6] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of cholestatic liver diseases. J Hepatol,2009,51（2）:237-267.
[7] 范作鹏,聂巍,梁珊,等. 北京地区药物性肝衰竭临床特点分析.北京医学,2015,37（9）:846-849.
[8] Hou FQ,Zeng Z,Wang GQ. Hospital admissions for drug-induced liver injury:clinical features,therapy,and outcomes. Cell Biochem Biophys,2012,64（2）:77-83.
[9] Andrade RJ,Lucena MI,Kaplowitz N,et al. Outcome of acute idiosyncratic drug-induced liver injury:Long-term follow-up in a hepatotoxicity registry. Hepatology,2006,44（6）:1581-1588.
[10] 赖荣陶,王晖,桂红莲,等. 138例药物性肝损伤患者的临床特征及肝脏组织学改变. 中华肝脏病杂志,2012,20（3）:185-189.
[11] Andrade RJ,Lucena MI,Kaplowitz N,et a1．Outcome of acute idiosyncratic drug-induced liver injury：Long term follow up in a hepatotoxicity registry．Hepatology,2006,44（6）：1581-1588．
[12] 朱雯静,赵新颜,马红. 慢性药物性肝损伤的研究进展.中华肝脏病杂志,2015,23（9）:718-720.
[13] Russo MW,Galanko JA,Shrestha R,et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transplant,2004,10（8）:1018-1023.
[14] 张义红,张义卫. 熊去氧胆酸治疗老年人胆汁淤积型药物性肝损伤临床疗效分析. 肝脏,2013,18（10）：685-686.
[15] 陈东风,孙文静,熊吉. 药物性肝损伤的诊断与治疗. 中华肝脏病杂志,2012,20（3）:170-172.
[16] 朱超慧,董迎华,艾正琳,等. 药物性胆汁淤积型肝病的治疗研究. 胃肠病学和肝病学杂志,2014,23（1）:90-93.
[17] 明雅南,刘晓琳,茅益民. 药物性肝损伤发病机制研究进展.实用肝脏病杂志,2014,17（6）：657-660.
[18] 韩平,田德安. 肝内胆汁淤积发病机制及药物治疗新进展. 胃肠病学和肝病学杂志,2016,25（5）:584-588.
[19] Aithal GP,Watkins PB,Andrade RJ,et a1. Case definition and phenotype standardization in drug-induced liver injury．Clin Pharmacol Ther,2011,89（6）：806-815.
[20] Borraz Y,Fernandez MC,Garcia-Muhoz B,et al. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury （DILI） 61st Annual Meeting of the American Association for the Study of Liver Diseases:2010,A270.
[21] Ju HY,Jang JY,Jeong SW,et al. The clinical features of drug-induced liver injury observed through liver biopsy:focus on relevancy to autoimmune hepatitis. Clin Mol Hepatol,2012,18（2）:213-218.

[1]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[2]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[3]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[4]	陆伦根. 胆汁淤积性肝病的正确认识与科学管理[J]. 实用肝脏病杂志, 2019, 22(5): 754-757.
[5]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[6]	庄太平, 尹杨艳, 谢蔓芳, 冯乃超, 陈彩华. 人巨细胞病毒感染与肝炎综合征婴儿临床特点比较^*[J]. 实用肝脏病杂志, 2019, 22(4): 514-517.
[7]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[8]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[9]	刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点[J]. 实用肝脏病杂志, 2019, 22(2): 160-163.
[10]	黄春洋,单晶,廖慧钰,黄云丽,韩莹,张小丹,杜晓菲,任美欣,边新渠,刘燕敏. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 208-211.
[11]	吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 212-215.
[12]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[13]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[14]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[15]	张小舟,帅领,王庆大,杨楠. 接受TACE治疗的肝细胞癌患者血清miR-335水平变化及其对预后判断的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 268-271.

合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*

Features of chronic cholestatic liver disease,as a kind of drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价